Antifugetactic agents for the treatment of cancers

Abstract

This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response.

1 - 38 . (canceled) 
     
     
         39 . A method for increasing the migratory capacity of immune cells into a mammalian renal tumor exhibiting fugetactic activity on said immune cells due to CXCL12 secretion, wherein said immune cells comprise tumor antigen-specific T-cells, which method comprises:
 a) selecting a mammal having said tumor which secretes a fugetactic effective amount of CXCL12 around said tumor;   b) contacting said T-cells with an anti-fugetactic concentration of 1,1′-[1,4-phenylenebis-(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] of 0.08 μg/mL to 5 μg/mL wherein said T-cells are now capable of increasing their migration into said tumor through the fugetactic activity of said tumor.   
     
     
         40 . The method of  claim 39 , wherein the renal tumor is an adenocarcinoma. 
     
     
         41 . The method of  claim 39 , wherein the renal tumor is a Wilms tumor. 
     
     
         42 . The method of  claim 39 , wherein said method further comprises administering anti-cancer therapy to the patient. 
     
     
         43 . The method of  claim 39 , wherein the anti-fugetactic agent is in a sustained release formulation. 
     
     
         44 . The method of  claim 39 , wherein the mammal is a human.